GSK (GLAXF) 10-Year RORE % : 30.44% (As of Mar. 2026)


GLAXF GSK PLC GLAXF
75 GF Score
Price $25.33
GF Value $21.09
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK 10-Year RORE %?

GSK GLAXF 75 10-Year RORE % is 30.44 as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.09 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 668 Drug Manufacturers companies, GSK ranks better than 83.08% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. GSK's 10-Year RORE % for the quarter that ended in Mar. 2026 was 30.44%.

The industry rank for GSK's 10-Year RORE % or its related term are showing as below:

GLAXF's 10-Year RORE % is ranked better than
83.08% of 668 companies
in the Drug Manufacturers industry
Industry Median: 6.27 vs GLAXF: 30.44

GSK  (OTCPK:GLAXF) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


GSK 10-Year RORE % Related Terms


GSK 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for GSK's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK 10-Year RORE % Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.67 51.36 8.20 -52.45 39.53

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.32 37.53 49.00 39.53 30.44

GLAXF vs LLY, JNJ, ABBV: 10-Year RORE % Comparison

For the Drug Manufacturers - General subindustry, GSK's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK 10-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where GSK's 10-Year RORE % falls into.


GLAXF
75GF Score
GSK PLC GLAXF
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK 10-Year RORE % Calculation

GSK's 10-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 1.917-0.521 )/( 15.61-11.024 )
=1.396/4.586
=30.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 30.44 mean?
GSK (GLAXF) has a 10-Year RORE % of 30.44 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on GSK and its competitors. According to the industry distribution chart, GSK ranks #113 out of 668 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is GSK's 10-Year RORE % too high?
GSK's current 10-Year RORE % is 30.44. The Drug Manufacturers industry median 10-Year RORE % is 6.27. GSK's value of 30.44 is 385.5% above this industry median. Based on the distribution chart, GSK ranks #113 out of 668 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's 10-Year RORE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #113 out of 668 companies for 10-Year RORE %. This places GSK in the top 17% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 6.27. GSK's value of 30.44 is 385.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.27, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current 10-Year RORE % of 30.44 is 385.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current 10-Year RORE % is 30.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.09, compared to a current price of $25.33 — trading 20.1% above its estimated fair value. The current 10-Year RORE % is 30.44 and 385.5% above the Drug Manufacturers industry median of 6.27. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For GSK (GLAXF), the current 10-Year RORE % is 30.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $25.33 is trading 20.1% above its estimated GF Value™ of $21.09. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • 10-Year RORE %: 30.44
  • GF Value™: $21.09 vs. price of $25.33 (20.1% above fair value)
  • GF Score™: 75/100 with 1 warning sign
  • Industry Position: 385.5% above the Drug Manufacturers median (#113 of 668)

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score

Get the complete analysis for GLAXF

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.33
Price
$21.09
GF Value